        {"rss":{"version":"2.0","channel":{"copyright":"Copyright (c) 2024 Yahoo Inc. All rights reserved.","description":"Latest Financial News for AADI","image":{"height":"45","link":"http://finance.yahoo.com/q/h?s=AADI","title":"Yahoo! Finance: AADI News","url":"https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png","width":"144"},"item":[{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, taking place January 18-20, 2024, in San Francisco, CA.","guid":"7840a59d-be57-3fa5-88d2-773bc07f4873","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-poster-presentations-210500723.html?.tsrc=rss","pubDate":"Fri, 19 Jan 2024 21:05:00 +0000","title":"Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations.","guid":"81f276b9-92c9-3308-89ed-8ddb8d0d6827","link":"https://finance.yahoo.com/news/aadi-bioscience-reports-interim-results-210500054.html?.tsrc=rss","pubDate":"Thu, 14 Dec 2023 21:05:00 +0000","title":"Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations"},{"description":"Key Insights Institutions' substantial holdings in Aadi Bioscience implies that they have significant influence over...","guid":"a4c353f3-1ca8-30fb-9281-f2489558c452","link":"https://finance.yahoo.com/news/aadi-bioscience-inc-nasdaq-aadi-111216194.html?.tsrc=rss","pubDate":"Wed, 13 Dec 2023 11:12:16 +0000","title":"Aadi Bioscience, Inc. (NASDAQ:AADI) is definitely on the radar of institutional investors who own 39% of the company"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced financial results for the quarter ended September 30, 2023, and highlighted recent corporate progress.","guid":"5c9bacc7-92a2-3624-ac90-ace1c5d605fc","link":"https://finance.yahoo.com/news/aadi-bioscience-reports-financial-results-130000988.html?.tsrc=rss","pubDate":"Wed, 08 Nov 2023 13:00:00 +0000","title":"Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023, in London. Dave Lennon, Ph.D., President and CEO, will participate in a fireside chat on Tuesday, November 14, 2023, at 8:30 am GMT.","guid":"6a32095f-fdad-35f4-b1f3-272cc47e03db","link":"https://finance.yahoo.com/news/aadi-bioscience-participate-jefferies-london-210500961.html?.tsrc=rss","pubDate":"Mon, 06 Nov 2023 21:05:00 +0000","title":"Aadi Bioscience to Participate in Jefferies London Healthcare Conference"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023 at 8:30 am ET (5:30 am PT) to report third quarter 2023 financial results and provide an operational update.","guid":"dabf6af8-65b7-3544-ac3a-5fbc89d4698e","link":"https://finance.yahoo.com/news/aadi-bioscience-report-third-quarter-200500270.html?.tsrc=rss","pubDate":"Wed, 01 Nov 2023 20:05:00 +0000","title":"Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea.","guid":"ecd2d819-24de-397e-b845-9452b085a4bf","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-poster-presentations-200500872.html?.tsrc=rss","pubDate":"Thu, 19 Oct 2023 20:05:00 +0000","title":"Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced details of four poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, MA.","guid":"f6d4e218-ccde-3521-ac5c-4e228c2f58a9","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-poster-presentations-200500455.html?.tsrc=rss","pubDate":"Thu, 12 Oct 2023 20:05:00 +0000","title":"Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that two posters will be presented at the upcoming North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, taking place October 4-6, 2023, in Montreal, Canada.","guid":"77cfd60c-c0b7-394e-95cd-9d9e594dc147","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-poster-presentations-200500531.html?.tsrc=rss","pubDate":"Thu, 05 Oct 2023 20:05:00 +0000","title":"Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that an equity award has been granted to its new President and Chief Executive Officer, Dave Lennon, Ph.D., on October 2, 2023, the first date of his employment (the \"Grant Date\"), in accordance with the Aadi Bioscience, Inc. 2023 Inducement Plan (the \"Plan\"). The award was granted pursuant to the terms of Dr.","guid":"2863b1be-0b3d-35af-884f-f2462138792d","link":"https://finance.yahoo.com/news/aadi-bioscience-grants-ceo-dave-200500000.html?.tsrc=rss","pubDate":"Tue, 03 Oct 2023 20:05:00 +0000","title":"Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathway alterations, today announced the appointment of Dave Lennon, Ph.D. as President and Chief Executive Officer. Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases. Dr. Lennon has also","guid":"7ac5e985-ebff-3b5e-ae96-48b2ae3ac8c3","link":"https://finance.yahoo.com/news/aadi-bioscience-appoints-dave-lennon-120000990.html?.tsrc=rss","pubDate":"Mon, 02 Oct 2023 12:00:00 +0000","title":"Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway alterations, announced today participation at the following investor events:","guid":"d3358e30-6d39-344d-90de-6d7040eba339","link":"https://finance.yahoo.com/news/aadi-bioscience-participate-upcoming-investor-120000525.html?.tsrc=rss","pubDate":"Tue, 05 Sep 2023 12:00:00 +0000","title":"Aadi Bioscience to Participate at Upcoming Investor Conferences"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.","guid":"f12a9d8b-8b2e-3be5-8b1f-50b04d808af9","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-financial-results-120000312.html?.tsrc=rss","pubDate":"Wed, 09 Aug 2023 12:00:00 +0000","title":"Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, August 9, 2023 at 8:30 am ET (5:30 am PT) to report second quarter 2023 financial results and provide an operational update.","guid":"3ec0d29d-cab1-3c9c-86c7-65debe77956a","link":"https://finance.yahoo.com/news/aadi-bioscience-report-second-quarter-120000447.html?.tsrc=rss","pubDate":"Wed, 02 Aug 2023 12:00:00 +0000","title":"Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL. The abstracts associated with the poster presentations are now available on the ASCO meeting website.","guid":"a73e12b0-f7fb-35d4-ad2b-cb3f2a82672e","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-presentations-2023-213000906.html?.tsrc=rss","pubDate":"Thu, 25 May 2023 21:30:00 +0000","title":"Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation at the following investor events:","guid":"d58ea148-76f0-3628-a8d5-f96a203e901a","link":"https://finance.yahoo.com/news/aadi-bioscience-participate-upcoming-investor-120000551.html?.tsrc=rss","pubDate":"Tue, 23 May 2023 12:00:00 +0000","title":"Aadi Bioscience to Participate in Upcoming Investor Events"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced financial results for the first quarter of 2023 and provided an initial update on the tumor-agnostic PRECISION 1 trial, a registration-directed Phase 2 study of nab-sirolimus in patients with solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes.","guid":"2fc6e81f-fc10-30fc-9595-b861145af0a5","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-financial-results-120000435.html?.tsrc=rss","pubDate":"Wed, 10 May 2023 12:00:00 +0000","title":"Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, May 10, 2023 at 8:30 am ET (5:30 am PT) to report first quarter 2023 financial results and provide an operational update.","guid":"23383240-bb46-3a5e-83ea-5d35ab34b363","link":"https://finance.yahoo.com/news/aadi-bioscience-report-first-quarter-120000432.html?.tsrc=rss","pubDate":"Wed, 03 May 2023 12:00:00 +0000","title":"Aadi Bioscience to Report First Quarter 2023 Results and Operational Update"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.","guid":"4258510c-3e0a-31bb-9731-f728a0b97d70","link":"https://finance.yahoo.com/news/aadi-bioscience-announces-multiple-presentations-200500822.html?.tsrc=rss","pubDate":"Wed, 26 Apr 2023 20:05:00 +0000","title":"Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting"},{"description":"Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.","guid":"dce6752e-7c35-351c-889c-55d4a7d92c6b","link":"https://finance.yahoo.com/news/aadi-bioscience-present-multiple-posters-170000662.html?.tsrc=rss","pubDate":"Fri, 14 Apr 2023 17:00:00 +0000","title":"Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting"}],"language":"en-US","lastBuildDate":"Thu, 25 Jan 2024 05:57:53 +0000","link":"http://finance.yahoo.com/q/h?s=AADI","title":"Yahoo! Finance: AADI News"}}}
